At close: December 13 at 4:00:01 PM EST
After hours: December 13 at 7:21:38 PM EST
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 2 | 7 | 7 |
| Avg. Estimate | -1 | -1.28 | -2.19 | -3.88 |
| Low Estimate | -1.21 | -1.34 | -2.41 | -5.62 |
| High Estimate | -0.58 | -1.22 | -1.78 | -0.38 |
| Year Ago EPS | -1.26 | -1.34 | -2.76 | -2.19 |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 2 | 8 | 8 |
| Avg. Estimate | 8.35M | -- | 141.38M | 78.1M |
| Low Estimate | -- | -- | 133M | -- |
| High Estimate | 50M | -- | 183.03M | 300M |
| Year Ago Sales | 316k | 50k | 91.37M | 141.38M |
| Sales Growth (year/est) | 2,542.37% | -100.00% | 54.73% | -44.75% |
Earnings History
| Currency in USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -1.19 | -1.22 | -1.03 | -1.18 |
| EPS Actual | -1.26 | -1.34 | 1.22 | -1.1 |
| Difference | -0.07 | -0.12 | 2.26 | 0.08 |
| Surprise % | -5.78% | -9.99% | 217.87% | 6.58% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1 | -1.28 | -2.19 | -3.88 |
| 7 Days Ago | -1 | -1.28 | -2.19 | -3.88 |
| 30 Days Ago | -1.01 | -1.41 | -2.3 | -4.18 |
| 60 Days Ago | -1 | -1.41 | -2.28 | -4.18 |
| 90 Days Ago | -1 | -1.41 | -2.28 | -4.19 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 4 | -- | 5 | 6 |
| Up Last 30 Days | 4 | -- | 5 | 6 |
| Down Last 7 Days | 2 | -- | 2 | 1 |
| Down Last 30 Days | 2 | -- | 2 | 1 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| PRTA | 20.98% | 4.48% | 20.65% | -77.17% |
| S&P 500 | 5.00% | 12.00% | 2.10% | 12.20% |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/13/2024 |
| Maintains | B of A Securities: Neutral to Neutral | 10/1/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 10/1/2024 |
| Reiterates | Cantor Fitzgerald: Overweight | 9/30/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 8/14/2024 |
| Reiterates | Cantor Fitzgerald: Overweight | 8/12/2024 |
Related Tickers
NMRA Neumora Therapeutics, Inc.
10.32
-2.46%
PTGX Protagonist Therapeutics, Inc.
41.08
+1.73%
ANAB AnaptysBio, Inc.
15.59
+3.79%
CYTK Cytokinetics, Incorporated
48.65
-3.16%
MRUS Merus N.V.
42.83
+3.33%
SLRN Acelyrin, Inc.
3.2300
-8.76%
VRDN Viridian Therapeutics, Inc.
17.85
-0.78%
OKUR OnKure Therapeutics, Inc.
9.86
-8.96%
VYGR Voyager Therapeutics, Inc.
6.27
+0.32%
LXEO Lexeo Therapeutics, Inc.
6.88
-3.51%